Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation

NCT01767792 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT01767792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01767792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 2
Overall status
Completed
Start date
May 15, 2013
Completion date
February 1, 2020
Enrollment
22 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

neurofibromatosis type 2, progressive vestibular schwannomas